Compare SHIM & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | IVVD |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 437.1M |
| IPO Year | 2023 | 2021 |
| Metric | SHIM | IVVD |
|---|---|---|
| Price | $3.50 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 32.5K | ★ 1.8M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $480,236,000.00 | $53,426,000.00 |
| Revenue This Year | $6.91 | $143.48 |
| Revenue Next Year | $13.03 | $25.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.30 | $0.46 |
| 52 Week High | $4.47 | $3.07 |
| Indicator | SHIM | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 57.32 |
| Support Level | $3.35 | $1.41 |
| Resistance Level | $3.50 | $2.01 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 11.59 | 96.00 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.